Research
Hormonal
Tirzepatide does not increase the risk of major adverse cardiovascular events (MACEs) in patients with type 2 diabetes.
Tirzepatide does not increase the risk of major adverse cardiovascular events (MACEs) in patients with type 2 diabetes. This makes it a safe option for cardiovascular risk management.
GoodRefutesHIGH confidence
Although the clinical relevance of the aforementioned cardiovascular risk factor alterations by tirzepatide will be assessed in the planned cardiovascular outcome study SURPASS-CVOT (NCT04255433), a pre-specified cardiovascular meta-analysis indicated that tirzepatide did not increase the risk of MACEs in participants with T2DM compared with controls.
Why this rating
Based on a pre-specified meta-analysis of phase 3 trials.
Source
The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist
Yun Kyung Cho et al. · Journal of Lipid and Atherosclerosis · 2023
DOI 10.12997/jla.2023.12.3.213
narrative_reviewCited 52×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide significantly reduces body weight and improves lipid profiles (lowering LDL-C and triglycerides, raising HDL-C) in patients with T2DM and obesity.Strong
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces systolic and diastolic blood pressure in patients with type 2 diabetes and obesity.Good
- Tirzepatide reduces inflammatory markers associated with cardiovascular risk, including YKL-40, ICAM-1, leptin, and GDF-15.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →